Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy: An open-label multicenter study

Epilepsy and Behavior

Volumn 16, Issue 3, 2009, Pages 468-474

  Wu, Tony ^a   Chen, Chih Chuan ^b   Chen, Ta Cheng ^c   Tseng, Yuan Fu ^d   Chiang, Chen Bang ^e   Hung, Chin Chuan ^f   Liou, Horng Huei ^b,e  

^a Chang Gung Memorial University   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cognitive function; Levetiracetam; Neuropsychological function; Quality of life

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADULT; ARTICLE; BRADYKINESIA; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISABILITY; DISEASE CONTROL; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; HEADACHE; HOSPITALIZATION; HUMAN; LANGUAGE PROCESSING; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTICENTER STUDY; NEUROPSYCHOLOGY; OPEN STUDY; PARANOIA; PATIENT ASSESSMENT; QUALITY OF LIFE; QUALITY OF LIFE IN EPILEPSY 10; QUALITY OF LIFE INDEX; RASH; RECALL; SIDE EFFECT; SOCIAL ADAPTATION; SOMNOLENCE; SYMPTOM CHECKLIST 90; TREATMENT RESPONSE;

ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; COGNITION DISORDERS; EPILEPSY; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PERCEPTION; PIRACETAM; PROSPECTIVE STUDIES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TAIWAN; TIME FACTORS;

EID: 70350620152     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2009.08.026     Document Type: Article

References (34)

1. Chaisewikul R, Privitera MD, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane Database Systemic Rev 2001:CD001901.
2. Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., and Falter U. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69 (2007) 1751-1760
3. Brodie M.J., Perucca E., Ryvlin P., Ben Menachem E., and Meencke H.J. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 (2007) 402-408
4. Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., and Schiemann-Delgado J. For the N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70 (2008) 607-616
5. Surges R., Volynski K.E., and Walker M.C. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action revisited. Ther Adv Neurol Disord 1 (2008) 13-24
6. Ben-Menachem E., and Falter U. For the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000d in patients with refractory partial seizures: a multi-center double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283
7. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I.E. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
8. Shorvon S.D., Lowenthal A., Janz D., Bielen E., and Loiseau P. For the European Levetiracetam Study Group. Multi-center double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
9. Meador K.J., Gevins A., Loring D.W., et al. Neuro-psychological and neuro-physiologic effects of carbamazepine and levetiracetam. Neurology 69 (2007) 2076-2084
10. Pigeolet E., Jacqmin P., Sargentini-Maier M.L., and Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin Pharmacokinet 46 (2007) 503-512
11. Tsai J.J., Yen D.J., Hsih M.S., et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multi-center, randomized, double-blind placebo-controlled study. Epilepsia 47 (2006) 77-81
12. Heo K., Lee B.I., Yi S.D., et al. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multi-center open-label single-arm trial in Korean patients. Seizure 16 (2007) 4029
13. Wu X.Y., Hong Z., Wu X., et al. Multi-center double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Epilepsia 50 (2008) 398-405
14. Zhao Q., Jiang J., Li X., Lu Z.S., and Hu P. Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br J Clin Pharmacol 63 (2007) 614-617
15. Zhou B., Zhang Q., Tian L., Xiao J., Stefan H., and Zhou D. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav 12 (2008) 305-310
16. Lutz M.T., and Helmstaedter C. EpiTrack: tracking cognitive side effects of medication on attention and executive functions in patients with epilepsy. Epilepsy Behav 7 (2005) 708-714
17. French J., Edrich P., and Cramer J.A. A systematic review of the safety profile of levetiracetam: a new anti-epileptic drug. Epilepsy Res 47 (2001) 77-90
18. Cramer J.A., Arrigo C., Van Hammee G., Gauer L.J., and Cereghino J.J. For the N132 Study Group. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 41 (2000) 868-874
19. White J.R., Walczak T.S., Leppik I.E., et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 61 (2003) 1218-1221
20. Hurtado B., Koepp M.J., Sander J.W., and Thompson P.J. The impact of levetiracetam on challenging behavior. Epilepsy Behav 8 (2006) 588-592
21. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
22. Folstein M.F., Folstein S.E., and Mchugh P.R. 'Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
23. Derogatis L.R. Symptom Checklist-90-R (SCL-90-R): administration, scoring and procedures manual. 3rd ed. (1994), National Computer Systems, Minneapolis
24. Green B.L., Gleser G.C., and Stone W.N. Seifert RF Relationships among diverse measures of psychotherapy outcome. J Consult Clin Psychol 43 (1975) 689-699
25. Cramer J.A. Quality of life assessments in epilepsy. In: Spilker B. (Ed). Quality of life and pharmacoeconomics in clinical trials (1996), Lippincott-Raven, Philadelphia 909-918
26. Steinhoff B.J., Somerville E.R., Van Paesschen W., Ryvlin P., and Schelstraete I. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res 76 (2007) 6-14
27. Ferrendelli J.A., French J., Leppik I.E., et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav 4 (2003) 702-709
28. Helmstaedter C., and Witt J.A. The effects of levetiracetam on cognition: a non-interventional surveillance study. Epilepsy Behav 13 (2008) 642-649
29. Piazzini A., Chifari R., Canevini M.P., Turner K., Fontana S.P., and Canger R. Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy. Epilepsy Res 68 (2006) 181-188
30. Genton P., and Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2 (2000) 99-105
31. Liou H.H., Chen R.C., Chen C.C., Chiu M.J., Chang Y.Y., and Wang J.D. Health related quality of life in adult patients with epilepsy compared with a general reference population in Taiwan. Epilepsy Res 64 (2005) 151-159
32. Ciesielski A.S., Samson S., and Steinhoff B. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav 9 (2006) 424-431
33. Dinkelacker V., Dietl T., Widman G., Lengler U., and Elger C.E. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 4 (2003) 537-547
34. Beavis J., Meek A., Felce D., and Kerr M. A prospective multi-centre open label study of the use of levetiracetam as add-on treatment of epilepsy and intellectual disabilities. Seizure 18 (2009) 279-284